CYTT Stock Overview
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cyteir Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.01 |
| 52 Week High | US$3.19 |
| 52 Week Low | US$1.65 |
| Beta | 0.096 |
| 1 Month Change | -1.63% |
| 3 Month Change | -2.27% |
| 1 Year Change | 77.06% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.70% |
Recent News & Updates
Recent updates
Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Deliver On Growth Plans?
Oct 25
Cyteir Therapeutics GAAP EPS of -$0.34
Aug 08Cyteir Therapeutics (NASDAQ:CYT) Is In A Good Position To Deliver On Growth Plans
Jul 21Here's Why We're Not Too Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Situation
Apr 21Companies Like Cyteir Therapeutics (NASDAQ:CYT) Are In A Position To Invest In Growth
Jan 06We're Not Very Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate
Sep 21Cyteir Therapeutics closes lower on first day of trading
Jun 18Shareholder Returns
| CYTT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | 0.1% | 2.2% |
| 1Y | 77.1% | -1.0% | 22.8% |
Return vs Industry: CYTT exceeded the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: CYTT exceeded the US Market which returned 29% over the past year.
Price Volatility
| CYTT volatility | |
|---|---|
| CYTT Average Weekly Movement | 2.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYTT has not had significant price volatility in the past 3 months.
Volatility Over Time: CYTT's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 46 | Markus Renschler | cyteir.com |
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
Cyteir Therapeutics, Inc. Fundamentals Summary
| CYTT fundamental statistics | |
|---|---|
| Market cap | US$108.33m |
| Earnings (TTM) | -US$33.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs CYTT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.22m |
| Earnings | -US$33.21m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CYTT perform over the long term?
See historical performance and comparison